

Editorial

Towards a better prevention in cardio-kidney metabolic syndrome: Role of aldosterone and albuminuria

*Hacia una mejor prevención del síndrome cardiorrenometabólico: papel de la aldosterona y la albuminuria*Luis M. Ruilope^{a,b,c}, Bertram Pitt^d, Alejandro de la Sierra^e, Gema Ruiz-Hurtado^{a,f,g,*}^aCardiorenal Translational Laboratory, Imas12 Research Institute, Hospital Universitario 12 de Octubre, Madrid, Spain^bCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Instituto de Salud Carlos III, Madrid, Spain^cEuropean University of Madrid, Madrid, Spain^dDivision of Cardiology, University of Michigan School of Medicine, Ann Arbor, MI, USA^eHypertension Unit, Department of Internal Medicine, Hospital Mutua Terrassa, University of Barcelona, Terrassa, Spain^fDepartment of Physiology, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain^gRICORS2040-Renal, 28040 Madrid, Spain

Pharmacological treatment of patients with hypertension and elevated cardiorenal risk has been classically based on the chronic blockade of the renin-angiotensin-system (RAS), with either angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). If necessary, other antihypertensive drugs have been commonly added, mainly diuretics and calcium antagonists. Theoretically, this approach prevents the development and progression of albuminuria and retards the progressive decay in renal function while acting positively on the simultaneous increased cardiovascular risk. Albuminuria is an established risk factor for the simultaneous development of chronic kidney disease (CKD) and cardiovascular disease. All this has promoted the concept and the clinical use of cardiorenal disease that more recently has been expanded as the new concept of cardio-kidney-metabolic (CKM) syndrome.¹

Although the beneficial effects of chronic RAS blockade have been largely recognized, it is also evident that a residual risk remains for both CKD and cardiovascular disease development and progression. Indeed, we have observed that the classical scheme of antihypertensive treatment described above was unable to completely prevent the development of new onset albuminuria and its progression, as well as the accompanying cardiorenal risk.² Additionally, the role of aldosterone in CKM syndrome has been recently recognized and the use of antialdosterone drugs considered.³ In fact, some individuals show elevated plasma aldosterone levels under chronic RAS blockade, known as aldosterone escape phenomenon.⁴ However, the excessive secretion of aldosterone plays a crucial role in the progression of cardiorenal disease. Unfortunately, despite its strong relevance, it remains clinically underappreciated. In fact, the need to measure plasma and urine aldosterone levels has been stressed.⁵ In recent trials

of new drugs in diabetic patients treated with the classical scheme blocking RAS plus antihypertensive and antidiabetic drugs, high and very high albuminuria and cardiovascular damage were already present.^{6–8} These trials have demonstrated that counteracting aldosterone was protective for the renal and cardiovascular damage in type 2 diabetes mellitus (T2DM). A deleterious role of aldosterone in different clinical situations under CKM context is already present even in the early stages of cardiorenal disease particularly, but not exclusively, in people with obesity and T2DM, thus facilitating the development of arterial hypertension, CKD, and heart failure (HF).³

The role of aldosterone in arterial hypertension was initiated decades ago by the description of primary aldosteronism and the possibility of curing hypertension with surgery. Medical treatment of primary aldosteronism initially included the administration of spironolactone. The prevalence of this secondary cause of hypertension was considered as very low, but nowadays, we know that primary aldosteronism is much more frequently present.⁹ A higher prevalence led to the conclusion that, in the hypertensive population, an adequate blood pressure control requires an adequate recognition and treatment of aldosterone excess.¹⁰ Other aspects of interest relating aldosterone and blood pressure are the fact that high plasma aldosterone concentration is accompanied by a worse ambulatory blood pressure monitoring profile and higher prevalences of masked uncontrolled hypertension^{11,12} and resistant hypertension.^{13,14}

On the other hand, new data related to the spectrum of dysregulated aldosterone secretion with a low renin phenotype has been described in patients with early stages of essential hypertension as well as in normotensive individuals relating the development of hypertension, CKD and cardiovascular disease.¹⁵ This dysregulated aldosterone production is apparently prominently influenced by adrenocorticotrophic hormone (ACTH), and could be accompanied by high-normal albuminuria (values between 10 and 30 mg/g of

* Corresponding author.

E-mail addresses: gema.ruiz@uam.es, gema.ruiz@h12o.es (G. Ruiz-Hurtado).

creatinine).³ This multifactorial situation requires, first, an adequate identification of alterations in the renin-angiotensin-aldosterone system (RAAS) in clinical practice, and second, the demonstration of the benefit of administration of aldosterone blockers in individuals with low renin. Although evidence is lacking from prospective clinical studies of albuminuria, this indicates that plasma aldosterone concentration and the aldosterone/renin ratio may serve as potential therapeutic targets for the early prevention of CKM disease. And also, potentially of even greater importance is the recent finding that high serum aldosterone levels in patients with CKD are independently associated with an increased risk for kidney disease progression, irrespective of the presence of T2DM.³

In conclusion, clinical situations characterized by an increased activity of aldosterone are more prevalent than previously considered, and they extend from mildly elevated blood pressure accompanied by low renin to hypertension due to primary aldosteronism and/or resistant hypertension. The ability of aldosterone to damage the cardiovascular and renal systems is particularly elevated in the presence of CKM syndrome particularly in patients with obesity and/or T2DM. Therefore, the need to determine renin and aldosterone levels in plasma in clinical practice needs to be expanded, as well as the potential use of aldosterone blockers. In this sense, new drugs counteracting the effects of aldosterone, such as non-steroidal mineralocorticoid receptor antagonists and aldosterone synthase inhibitors have been developed and are being increasingly used in clinical practice.^{16,17} Therefore, it is highly recommended the search for urine albumin measurement and if possible the determination of aldosterone levels in patients at all the stages of CKM syndrome. Individuals with both albuminuria and elevated aldosterone levels could be candidates for such aldosterone inhibition as a relevant treatment of the CKM syndrome progression.

Acknowledgements

We thank the support of the projects from Instituto de Salud Carlos III (ISCIII) (PI20/00763, PI23/00182, RD24/0004/0018) co-funded by the European Union, Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (CNS2023-144891), and Biomedicine Network Comunidad de Madrid (P2022/BMD-7223 CIFRA_COR-CM).

References

1. Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American heart

- association. *Circulation*. 2023;148:1636–64, <http://dx.doi.org/10.1161/CIR.0000000000001186>
2. Cerezo C, Ruilope LM, Segura J, Garcia-Donaire JA, de la Cruz JJ, Banegas JR, et al. Microalbuminuria breakthrough under chronic renin–angiotensin–aldosterone system suppression. *J Hypertens*. 2012;30:204–9, <http://dx.doi.org/10.1097/HJH.0b013e32834d9e0f>
3. Ruilope LM, Ortiz A, Lucia A, Miranda B, Alvarez-Llamas G, Barderas MG, et al. Prevention of cardiorenal damage: importance of albuminuria. *Eur Heart J*. 2023;44:1112–23, <http://dx.doi.org/10.1093/eurheartj/ehac683>
4. Bombardier AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. *Nat Clin Pract Nephrol*. 2007;3:486–92, <http://dx.doi.org/10.1038/neph00575>
5. Bakris GL, Jaisser F. Aldosterone excess and cardiorenal risk: more common than appreciated. *Eur Heart J*. 2022;43:3792–3, <http://dx.doi.org/10.1093/eurheartj/ehac410>
6. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med*. 2020;383:2219–29, <http://dx.doi.org/10.1056/NEJMoa2025845>
7. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *N Engl J Med*. 2021;385:2252–63, <http://dx.doi.org/10.1056/NEJMoa2110956>
8. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. *Eur Heart J*. 2022;43:474–84, <http://dx.doi.org/10.1093/eurheartj/ehab777>
9. de Fremerville JB, Gardini M, Cremer A, Camelli S, Baron S, Bobrie G, et al. Prevalence and risk factors for secondary hypertension in young adults. *Hypertension*. 2024;81:2340–9, <http://dx.doi.org/10.1161/HYPERTENSIONAHA.124.22753>
10. Ruilope LM, Ruiz-Hurtado G, Tamargo J. Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism. *Trends Cardiovasc Med*. 2021, <http://dx.doi.org/10.1016/j.tcm.2021.04.003>
11. Siddiqui M, Judd EK, Zhang B, Dudenbostel T, Carey RM, Oparil S, et al. Masked uncontrolled hypertension is accompanied by increased out-of-clinic aldosterone secretion. *Hypertension*. 2021;77:435–44, <http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15950>
12. Morita R, Azushima K, Sunohara S, Haze T, Kobayashi R, Kinguchi S, et al. High plasma aldosterone concentration is associated with worse 24-h ambulatory blood pressure profile in patients with primary aldosteronism. *Hypertens Res*. 2023;46:1995–2004, <http://dx.doi.org/10.1038/s41440-023-01325-8>
13. Salvador VD, Bakris GL. Novel antihypertensive agents for resistant hypertension: what does the future hold? *Hypertens Res*. 2022;45:1918–28, <http://dx.doi.org/10.1038/s41440-022-01025-9>
14. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. *Lancet Diabetes Endocrinol*. 2018;6:464–75, [http://dx.doi.org/10.1016/S2213-8587\(18\)30071-8](http://dx.doi.org/10.1016/S2213-8587(18)30071-8)
15. Parksook WW, Brown JM, Omata K, Tezuka Y, Ono Y, Satoh F, et al. The spectrum of dysregulated aldosterone production: an international human physiology study. *J Clin Endocrinol Metab*. 2024;109:2220–32, <http://dx.doi.org/10.1210/clinem/dgae145>
16. Yoshida Y, Shibata H. Evolution of mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and alternative treatments for managing primary aldosteronism. *Hypertens Res*. 2024, <http://dx.doi.org/10.1038/s41440-024-01970-7>
17. Götzinger F, Kunz M, Lauder L, Böhm M, Mahfoud F. New ways of mitigating aldosterone in cardiorenal disease. *Eur Heart J Cardiovasc Pharmacother*. 2024;10:557–65, <http://dx.doi.org/10.1093/ehjcvp/pvae049>